CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's ...

J&J's diversified business, robust pipeline, and strong free cash flow provide stability, despite legal challenges. Read more ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

The FDA appears ready to reconsider its restrictions on therapeutic use of MDMA, ibogaine, and other drugs, but some worry ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. The healthcare-products company said Tuesday it now expects adjusted per-share ...

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.